A postdoctoral position is available in the Lipton lab at The Scripps Research Institute (TSRI) to study neurodevelopmental and neurodegenerative diseases using patient-derived human induced pluripotent stem cells (hiPSCs) as well as genetic mouse models. Our goal is to understand how specific gene mutations and posttranslational modifications that mimic the effect of such mutations, such as aberrant protein S-nitrosylation, contribute to synaptic damage. We also develop new drug therapies for these diseases. Ongoing research in the lab uses “disease-in-a-dish” models generated from hiPSCs in 2D cultures and 3D-brain organoids (“mini-brains”). A plethora of techniques are employed including chemical biology, molecular biology, patch-clamp electrophysiology and calcium imaging.
The candidate is expected to be highly motivated, possess an ability to troubleshoot and work well independently and with others. Tiissue culture and molecular biology experience is preferred.
Stuart Lipton, MD, PhD is Professor and Co-Director of the new Neuroscience Translational Center at TSRI. The laboratory is in the Departments of Molecular Medicine and Neuroscience, and is located in the Calibr Building for Drug Discovery on North Torrey Pines Road in La Jolla. We provide competitive salary, fringe benefits and scientific support plus a commitment to helping our trainees advance their careers.
We are looking for individuals who want to study both transgenic/knock out mouse and hiPSC-based models, and who meet the following criteria:
1) Ph.D. in neuroscience, biology, pharmacology, or a related field.
2) A track record of thoughtful scientific inquiry (e.g., first author publication).
3) Experience at the intersection of two or more of the following fields: Cell biology, molecular biology, biochemistry, confocal imaging/quantitative neurohistology, electrophysiology, pharmacology, data analysis.
The Lipton laboratory studies molecular mechanisms of neurodegenerative diseases and stroke, including the role of excessive stimulation of ion channels and intracellular signaling pathways in nerve cells. Among the laboratory's accomplishments and ongoing activities are (i) the development of the first glutamate receptor/channel antagonist drug (Memantine/Namenda®), representing the most recent t...herapeutic to be clinically approved for the treatment of Alzheimer's disease by the European Union and the FDA, (ii) discovery with colleagues of the posttranslational protein modification termed S-nitrosylation (reaction of NO with a critical thiol group to control protein function), (iii) characterization of signaling events leading to neuronal injury and apoptosis in AIDS, and (iv) discovery and cloning of the transcription factor MEF2C that programs human embryonic stem cells (hESCs) and induced pluripotent stem cells (hiPSCs) to become nerve cells in the brain and whose knock down in the brain of rodents and humans causes Autism Spectrum Disorder (ASD). These studies have led to the development of the first neuroprotective drugs to be administered successfully to humans to combat various neurodegenerative and vascular diseases of the brain.